Jump to content



Recommended Posts

The trial is at Mass General

One of the irreversible EGFR inhibitors used in this study – HKI-272, manufactured by Wyeth – is already in a phase 1 clinical trial. And MGH Cancer Center researchers are planning to lead a multi-institutional phase 2 trial in NSCLC patients whose tumors have sensitizing EGFR mutations but have become resistant to Iressa or Tarceva.

http://www.eurekalert.org/pub_releases/ ... 051105.php

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.